Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide.

Abstract

BACKGROUND:

Recommended treatment for cutaneous sporotrichosis consists of a saturated solution of potassium iodide (SSKI) administered in three daily doses (tid). Because compliance with this regimen has been a problem in our previous experience, we evaluated the use of one daily (qd) full dose of SSKI.

METHODS:

Patients with culture-confirmed cutaneous sporotrichosis were entered in a randomized, nonblinded study to compare the safety and efficacy of qd vs. tid dosage of SSKI.

RESULTS:

Fifty-seven patients were enrolled to receive either qd (29) or tid (28) SSKI. Three (1 in the qd and 2 in the tid group) were not compliant with the assigned regimen. Side effects were common but mild in both treatment groups (61% in the qd and 42% in the tid group, P = 0.17); treatment had to be discontinued because of side effects in 3 cases (2 in the qd and 1 in the tid group). Overall 26 (89.6%) and 25 (89.2%) of the individuals initially assigned to the qd and tid dosing schedule, respectively, were cured by the treatment. No relapse was detected after 45 days of follow-up.

CONCLUSION:

These findings suggest that a single daily full dose of SSKI appears to be appropriate therapy for cutaneous sporotrichosis; further studies with larger numbers of patients are required.

• Authors: C Cabezas, B Bustamante, W Holgado, R E Begue
• Journal: The Pediatric infectious disease journal (Pediatr Infect Dis J) Vol. 15 Issue 4 Pg. 352-4 (Apr 1996) ISSN: 0891-3668 [Print] United States
• PMID: 8866807 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Potassium Iodide

Topics

• Adolescent
• Child
• Child, Preschool
• Female
• Humans
• Male
• Potassium Iodide (administration & dosage, adverse effects, therapeutic use)
• Sporotrichosis (drug therapy)